Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL)
- 13 October 2009
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 21 (4) , 851-854
Abstract
Background: Splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes is an indolent lymphoma that typically affects elderly patients. Treatment is required in symptomatic cases. Splenectomy remains one of the first-line options in patients fit for surgery. The best therapeutic strategy has not yet been identified. Among different possible chemotherapeutic approaches, purine analogues, alone or in association with rituximab, seem to be a valid therapeutic choice. Patients and methods: Fifty SMZL patients were treated with cladribine with or without anti-CD20 mAb. Results: Forty-six of 50 patients were assessable for response. Overall response rate was 87%: 24 of 46 patients (52%) achieved a complete hematological response (CR), 16 of 46 (35%) a partial response and 6 (13%) were unresponsive. Interestingly, 15 of 24 cases (62%) in CR also achieved a molecular remission. Conclusions: The present results indicate that this schedule is a valid therapeutic approach in SMZL. Addition of rituximab significantly improved quality of response and consequently the outcome of the disease.Keywords
This publication has 24 references indexed in Scilit:
- Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow‐upBritish Journal of Haematology, 2008
- Splenic marginal zone lymphoma: a prognostic model for clinical useBlood, 2006
- Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy aloneCancer, 2006
- Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytesEuropean Journal of Haematology, 2005
- Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomasLeukemia, 2004
- Low dose 2‐CdA schedule activity in splenic marginal zone lymphomasHematological Oncology, 2003
- Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytesBritish Journal of Haematology, 2003
- Regression of Splenic Lymphoma with Villous Lymphocytes after Treatment of Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Lack of Efficacy of 2-Chlorodeoxyadenoside in the Treatment of Splenic Lymphoma with Villous LymphocytesLeukemia & Lymphoma, 2000
- Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patientsBritish Journal of Haematology, 1996